SG10202012106WA - Methods for treating inflammatory conditions of the lungs - Google Patents
Methods for treating inflammatory conditions of the lungsInfo
- Publication number
- SG10202012106WA SG10202012106WA SG10202012106WA SG10202012106WA SG10202012106WA SG 10202012106W A SG10202012106W A SG 10202012106WA SG 10202012106W A SG10202012106W A SG 10202012106WA SG 10202012106W A SG10202012106W A SG 10202012106WA SG 10202012106W A SG10202012106W A SG 10202012106WA
- Authority
- SG
- Singapore
- Prior art keywords
- lungs
- methods
- inflammatory conditions
- treating inflammatory
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201670991 | 2016-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202012106WA true SG10202012106WA (en) | 2021-01-28 |
Family
ID=61024712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202012106WA SG10202012106WA (en) | 2016-12-13 | 2017-12-13 | Methods for treating inflammatory conditions of the lungs |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11413328B2 (en) |
| EP (1) | EP3554532A2 (en) |
| JP (1) | JP2020512287A (en) |
| KR (1) | KR20190108106A (en) |
| CN (1) | CN110290799A (en) |
| AU (1) | AU2017376400A1 (en) |
| BR (1) | BR112019011844A2 (en) |
| CA (1) | CA3045079A1 (en) |
| MX (1) | MX2019006848A (en) |
| RU (1) | RU2019120956A (en) |
| SG (1) | SG10202012106WA (en) |
| WO (1) | WO2018108971A2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018363783A1 (en) * | 2017-11-10 | 2020-05-28 | Novozymes A/S | Maturation of mucosal defense and gut/lung function in the preterm infant |
| CN108815199B (en) * | 2018-08-03 | 2021-10-01 | 南华大学 | Application of mouse chlamydia in preparation of anti-ulcerative colitis medicine |
| US11331269B2 (en) * | 2018-09-06 | 2022-05-17 | Massachusetts Institute Of Technology | Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment |
| JP7479381B2 (en) | 2019-01-07 | 2024-05-08 | アエスクルス バイオ エーピーエス | DEFENSIN FRAGMENTS FOR THERAPEUTIC OR PROPHYLAXIS USE - Patent application |
| MX2021010912A (en) * | 2019-03-14 | 2021-10-01 | Om Pharma Sa | Process for making stable bacterial extracts and their use as pharmaceuticals. |
| CN113262297A (en) * | 2020-11-02 | 2021-08-17 | 中南大学湘雅二医院 | Therapeutic lung cancer vaccine based on pasteurella and preparation method and application thereof |
| CN113521047B (en) * | 2021-08-23 | 2022-10-04 | 新疆医科大学第四附属医院 | Application of butyrate in preparation of chronic obstructive pulmonary disease medicine |
| WO2023125432A1 (en) * | 2021-12-27 | 2023-07-06 | Versitech Limited | Antiviral peptides and methods of use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE4343591A1 (en) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Process for the evolutionary design and synthesis of functional polymers based on shape elements and shape codes |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| ES2500918T3 (en) | 2001-12-21 | 2014-10-01 | Human Genome Sciences, Inc. | Albumin and interferon beta fusion proteins |
| US7511015B2 (en) * | 2002-02-19 | 2009-03-31 | The United States Of America As Represented By The Department Of Health And Human Services | Modified defensins and their use |
| WO2003101394A2 (en) | 2002-05-31 | 2003-12-11 | Ciphergen Biosystems, Inc. | Defensins: use as antiviral agents |
| GB0521139D0 (en) | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
| US7528107B2 (en) | 2005-11-30 | 2009-05-05 | Auburn University | Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins |
| WO2008115390A2 (en) | 2007-03-16 | 2008-09-25 | The Hamner Institutes For Health Sciences | Methods of using defensins to treat diabetes |
| EP2237799B1 (en) | 2008-02-01 | 2019-04-10 | Ascendis Pharma A/S | Prodrug comprising a self-cleavable linker |
| SG172709A1 (en) * | 2008-07-18 | 2011-07-28 | Novozymes Adenium Biotech As | Treatment of inflammatory bowel diseases with mammal beta defensins |
| EA201170218A1 (en) | 2008-07-18 | 2011-08-30 | Новозимс Эдениум Байотек А/С | TREATMENT OF THE INFLAMMATORY DISEASES OF BETA-DEFENSINS OF MAMMALS |
| DK2396347T3 (en) | 2009-02-11 | 2017-07-24 | Albumedix As | ALBUMIN VARIANTS AND CONJUGATES |
| US8828380B2 (en) * | 2009-09-10 | 2014-09-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for the treatment of pulmonary disease and method of producing proteins of use therein |
| US8410049B2 (en) | 2009-10-28 | 2013-04-02 | Cebix | Methods and kits for preventing hypoglycemia |
| KR101329774B1 (en) | 2010-06-16 | 2013-11-15 | 주식회사 나이벡 | Antibacterial or Anti-inflammatory Peptides and Pharmaceutical Composition Containing Thereof |
| WO2012064601A1 (en) | 2010-11-08 | 2012-05-18 | Pulmatrix, Inc. | Methods of treating and preventing rhinovirus infection |
| WO2013007596A2 (en) | 2011-07-08 | 2013-01-17 | Novozymes A/S | Oral treatment of inflammatory bowel disease |
| WO2013026794A1 (en) | 2011-08-19 | 2013-02-28 | Novozymes | Novel immunomodulatory peptide |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| NZ708836A (en) * | 2012-12-06 | 2020-07-31 | Pin Pharma Inc | Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides |
| AU2018363783A1 (en) | 2017-11-10 | 2020-05-28 | Novozymes A/S | Maturation of mucosal defense and gut/lung function in the preterm infant |
-
2017
- 2017-12-13 MX MX2019006848A patent/MX2019006848A/en unknown
- 2017-12-13 CA CA3045079A patent/CA3045079A1/en active Pending
- 2017-12-13 WO PCT/EP2017/082535 patent/WO2018108971A2/en active Search and Examination
- 2017-12-13 JP JP2019531167A patent/JP2020512287A/en active Pending
- 2017-12-13 KR KR1020197019175A patent/KR20190108106A/en not_active IP Right Cessation
- 2017-12-13 AU AU2017376400A patent/AU2017376400A1/en active Pending
- 2017-12-13 SG SG10202012106WA patent/SG10202012106WA/en unknown
- 2017-12-13 EP EP17835461.9A patent/EP3554532A2/en active Pending
- 2017-12-13 US US16/468,051 patent/US11413328B2/en active Active
- 2017-12-13 CN CN201780086292.7A patent/CN110290799A/en active Pending
- 2017-12-13 RU RU2019120956A patent/RU2019120956A/en unknown
- 2017-12-13 BR BR112019011844A patent/BR112019011844A2/en not_active Application Discontinuation
-
2022
- 2022-07-11 US US17/861,912 patent/US20230067261A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018108971A3 (en) | 2018-07-26 |
| JP2020512287A (en) | 2020-04-23 |
| RU2019120956A3 (en) | 2021-04-13 |
| US11413328B2 (en) | 2022-08-16 |
| CN110290799A (en) | 2019-09-27 |
| WO2018108971A2 (en) | 2018-06-21 |
| AU2017376400A1 (en) | 2019-06-20 |
| KR20190108106A (en) | 2019-09-23 |
| BR112019011844A2 (en) | 2022-05-10 |
| CA3045079A1 (en) | 2018-06-21 |
| MX2019006848A (en) | 2019-10-07 |
| US20190336576A1 (en) | 2019-11-07 |
| US20230067261A1 (en) | 2023-03-02 |
| RU2019120956A (en) | 2021-01-15 |
| EP3554532A2 (en) | 2019-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266770A (en) | Methods of treating inflammatory conditions | |
| HK1251614A1 (en) | Method for the treatment of malignancies | |
| EP3359171C0 (en) | Use of akkermansia muciniphila for treating inflammatory conditions | |
| IL285151B1 (en) | Methods of treating fgf21-associated disorders | |
| IL279627A (en) | Method for the treatment of depression | |
| SG10202012106WA (en) | Methods for treating inflammatory conditions of the lungs | |
| IL253118A0 (en) | Methods of treating inflammatory diseases | |
| HK1252037A1 (en) | Methods of treating inflammatory diseases | |
| SG10201913400QA (en) | Methods for treating lung disorders | |
| PT3377064T (en) | Orvepitant for the treatment of chronic cough | |
| SG11201708181RA (en) | Methods for the treatment of inflammatory disorders | |
| HK1247558A1 (en) | Cenicriviroc for the treatment of fibrosis | |
| PL3292226T3 (en) | Method for the treatment of iron-containing sludge | |
| HK1210590A1 (en) | Method for the treatment of hypercholesterolemia | |
| HK1250624A1 (en) | Methods for the treatment of cardiovascular disorders | |
| GB201521543D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201513993D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201513345D0 (en) | Methods for the treatment of Inflammatory disorders | |
| GB201507113D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201506419D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201506229D0 (en) | Methods For the Treatment Of Inflammatory Disorders | |
| PT3420084T (en) | Novel approach for treating inflammatory disorders | |
| GB201701933D0 (en) | New methods for the treatment of hyperglycaemia | |
| GB201701936D0 (en) | New methods for the treatment of hyperglycaemia | |
| GB201516418D0 (en) | Treatment of acute inflammatory disorders |